Celldex reports that the first participant has received a dose in a Phase 1 study involving healthy volunteers for CDX-622.

LAPIX Therapeutics Reveals Favorable Phase 1 Clinical Trial Results for LPX-TI641 in Treating Autoimmune Disorders.

uniQure N.V. has announced that the initial patient has received the dose in the GenTLE Phase I/IIa clinical study of AMT-260.

Laekna has partnered with Lilly to advance LAE102, a new monoclonal antibody aimed at Activin Receptor Type 2A for obesity treatment.

The EC has given the green light to Pfizer’s HYMPAVZI™ (marstacimab) for treating severe Hemophilia A or B in adults and teens without inhibitors.

Eli Lilly and Company has announced encouraging Phase 2 findings for muvalaplin, which is a genetically linked risk factor for heart disease.

The global stem cell therapy market was valued at $10–12 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10–15%.

Nektar Therapeutics Shares Initial Preclinical Findings for its New CSF-1 Program, NKTR-422, at the 2024 ACR Convergence.

Tisotumab Vedotin-tftv is an antibody-drug conjugate (ADC) developed by Genmab and Seagen, a protein that is overexpressed in various solid tumors.

Icotrokinra provided impressive skin improvement and proven safety as a once daily tablet in Phase 3 results.

Tofersen, developed by Biogen in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the superoxide dismutase 1 (SOD1) mRNA.

Neurizon Therapeutics Limited is excited to report favorable outcomes from a preclinical evaluation of its primary candidate, NUZ-001.